GREY:IMVIF - Post by User
Post by
Breakthorough1on Aug 03, 2023 12:30pm
114 Views
Post# 35571445
November 11 2022
November 11 2022"As a result of our recent reorganization and cost reduction measures, we expect our 2023 average cash burn per quarter to remain consistent with 2022, despite forecasted increases in clinical costs due to the acceleration of our VITALIZE and AVALON trials.
We also know that good clinical data is a strong catalyst for institutional investment. With the acceleration of our clinical programs and the ability to see the clinical responses in real time, we believe, it could create a context favorable to improve our financial position."